A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo- Controlled, Parallel Group, Oral Multiple-Dose Trial to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-03882845 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 Feb 2010
At a glance
- Drugs PF 3882845 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 24 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 24 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.